Search
for
Sort by
Research 30 of 775
- JAK inhibitors in dermatology: The promise of a new drug class
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- JAK Inhibitors for Treatment of Alopecia Areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Under Development JAK Inhibitors for Dermatologic Diseases
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Keratin 6A promotes skin inflammation through JAK1-STAT3 activation in keratinocytes
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience